... and on the enhancement of capillary permeability, it is possible that this factor plays an important role in tumor progression. In human renal cell carcinoma (RCC), it has recently been reported that immunotherapy with interferon (IFN) is effective for the prevention of tumor recurrence and progression. To evaluate...

...N.K. Mohanty; P. Gulati; S. Saxena In order to study the tolerability, toxicity and therapeutic efficacy of interferon-α 2b (Intron-A), 20 patients with superficial transitional cell carcinoma (TCC) of the urinary bladder (T a , T 1 ) were given intravesically a low dose (9 million IU) of the drug...

...M. Wirth Cytokines such as interferons, interleukin-2 and tumor necrosis factor have been widely tested in the treatment of advanced renal cell cancer. However, the rates of objective remissions (PR and CR) are disappointing and rarely exceed 20% overall. Until now, a definitive cure of a patient...

...J.W. Grups; H.G.W. Frohmüller In order to evaluate the antiproliferative effects of recombinant human interferon-Γ 2c (rHu IFN-Γ 2c ), recombinant human interferon-Γ (rHu IFN-Γ), natural interferon-Β (IFN-Β), and their combination with cytotoxic agents, 17 different human bladder carcinoma cell...

...Detlef Rohde; Drasko Brkovic; Inga Hönig d’Orville Introduction: Conventional preclinical investigations have strongly recommended to combine interferon-α (IFN-α) with 13- cis retinoic acid (13-cRA, isotretinoin) for treatment of renal cell carcinoma (RCC). However, a recent randomized controlled...

... to immune status and response to immunotherapy remains problematic. We analyzed tumor-infiltrating lymphocyte (TIL) subsets to determine whether these correlated with the prognoses for the patients and the response to α-interferon therapy. Materials and Methods: TIL subsets from resected specimens of 79...